overweight or obese polycystic ovary syndrome
Conditions
Interventions
Group 1:Drospirenone and Ethinylestradiol Tablets(II)
Group 2:orlistat combined with Drospirenone and Ethinylestradiol Tablets(II)
Sponsors
Beijing Obstetrics and Gynecology Hospital, Capital Medical University
Eligibility
Sex/Gender
Female
Age
16 Years to 40 Years
Inclusion criteria
Inclusion criteria: 1. Chinese, female of reproductive age between 16 and 40 years old; 2. Overweight or obese patients with BMI=24kg/m2 and WC=80cm; 3. PCOS was diagnosed according to Rotterdam standard 2003. (1) Rare ovulation or anovulation: clinical manifestations are amenorrhea, oligomenorrhea, menarche 2-3 years can not establish regular menstruation and basic body temperature is uniphase. Sometimes menstruation is regular but no ovulation; (2) Clinical manifestations of hyperandrogen and hyperandrogenemia: clinical manifestations include acne and hypertrichosis; (3) Ovarian polycystic changes: B ultrasound examination showed that the diameter of one or both sides of the ovary 2-9 mm follicles=12 and/or ovarian volume=10cm3. Two of the above three conditions were consistent, and other diseases causing high androgen, such as congenital adrenal cortical hyperplasia, Cushing syndrome and androgen-secreting tumors, will be excluded. PCOS can be diagnosed.
Exclusion criteria
Exclusion criteria: 1. Hormone drugs or ovulation induction therapy were used in the first 3 months; 2. Suffering from a reproductive transmitted disease; 3. Suffering from serious genetic, physical or mental diseases; 4. One party is exposed to teratogenic rays, poisons and drugs and is in effect; 5. Endometriosis and adenomyosis; 6. Allergic to any one of the ingredients of all tested drugs; 7. Drug contraindication: (1) peptic ulcer or malabsorption syndrome; (2) History of recurrent gallstones and kidney stones; (3) Had been diagnosed as postoperative intestinal adhesion; (4) History of thrombosis (e.g., deep vein thrombosis, pulmonary embolism, myocardial infarction, cerebrovascular accident); 8. Liver function index exceeds normal value more than 2 times; 9. Malignant tumor patients; 10. A history of pancreatitis; 11. Receiving other drugs in the past 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| FSH;LH;E2;T;TSH;Insulin;serum lipid level;blood glucose level;liver function test;Renal function test;Visceral fat area;Subcutaneous fat area; | — |
Countries
China
Contacts
Public ContactXiangyan Ruan
Beijing Obstetrics and Gynecology Hospital, Capital Medical University
Outcome results
None listed